MEDEXPERT CONSULTING, INC.
INDIALANTIC, FLORIDA

Dena Grayson, MD, PhD (née Dena Minning) is a biotechnology entrepreneur with strong leadership skills, clear strategic vision, successful fundraising and business development experience, along with proven capabilities in developing drug candidates from lead optimization through NDA filing. Dr. Grayson played a key role in raising over $120m, including $55m from venture firms while serving as Vice President for two biotech companies. In addition, she played a central role in successfully procuring a $20+ million contract from the US Government, awarded for the development of a broad-spectrum antiviral drug active against Ebola, Zika and other deadly viruses. Dr. Grayson also possesses buy-side business development transactional experience in both Big Biopharma and emerging biotechnology settings with a deep understanding of effectively positioning companies for future partnering or M&A. In 2006, Dr. Grayson was recognized as one of America’s leading executives under the age of 45 when she was named a Henry Crown Fellow of the Aspen Institute. Dr. Grayson previously served as Vice President of Translational Medicine at 3-V Biosciences, where she oversaw preclinical and clinical development activities for the company’s host-directed antiviral therapeutics.  Prior to 3-V, Dr. Grayson held the position of Director in Early Development at Amgen, overseeing IND-enabling activities through Phase 2 clinical studies. As Early Development Leader and Clinical Scientist, she led multiple therapeutic programs in anemia, heart failure, asthma, dyslipidemia, myelodysplastic syndrome, and pain. While at Amgen, Dr. Grayson also served as Associate Director in Licensing and played a pivotal role in Amgen’s successful in-licensing transaction with Cytokinetics ($75m upfront, $50m option, plus other milestones). She subsequently represented Amgen on the partnership’s Joint Development Committee.   MedExpert Consulting, Inc. provides executive-level biotechnology consulting services for small molecule pharmaceuticals, large molecule biologics, cancer vaccines, and cell-based therapeutics in preclinical and clinical development.  Founded by Dena Grayson, MD, PhD (née Dena Minning), MedExpert Consulting leverages Dr. Grayson's unique combination of experience in drug development, fundraising, business development, and market research and forecasting to maximize the potential for success of new therapeutic candidates. MedExpert Consulting's clients include public and privately held biotechnology and pharmaceutical companies, and life sciences investors.